



#22 goiga
Patent

Attorney's Docket No. 029395-017

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 15 2003

TECH CENTER 1600/2900

In re Patent Application of)
Joyce TAYLOR-PAPADIMITRIOU et al.) Group Art Unit: 1644
Application No.: 09/658,621) Examiner: Amy M. Decloux
Filed: September 8, 2000) Confirmation No.: 3359
For: MUC-1 DERIVED PEPTIDES)

**INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$_____ is enclosed for the fee due.


The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

By:


Christopher L. North, Ph.D.
Registration No. 50,433

Date: April 11, 2003



Patent
Attorney's Docket No. 029395-017

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 15 2003

TECH CENTER 1600/2900

In re Patent Application of)
Joyce TAYLOR-PAPADIMITRIOU et al.) Group Art Unit: 1644
Application No.: 09/658,621) Examiner: Amy M. Decloux
Filed: September 8, 2000) Confirmation No.: 3359
For: MUC-1 DERIVED PEPTIDES)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since the documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b) no fee or statement is required.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: April 11, 2003

for: By: *Christopher L. North* Rpy. #45,635
Christopher L. North, Ph.D.
Registration No. 50,433

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Substitute for forms 1449A/PTO & 1449B/PTO

ATTORNEY'S DKT NO.
029395-017APPLICATION NO.
09/658,621APPLICANT
Joyce TAYLOR-PAPADMITRIOU et al.FILING DATE
September 8, 2000GROUP
1644 APR 15 2003INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation Yes	No
	00/06723		WO			
	98/50527		WO			
	0 369 816		EP			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
A-1	Pei-Xiang XIANG et al., "Synthetic Peptides Reactive with Anti-Human Milk Fat Globule Membrane Monoclonal Antibodies", Cancer Research, Vol. 50, No. 1, 1 January 1990, pp. 89-96, The American Association of Immunologists, Bethesda, MD
A-2	Vasso APOSTOLOPOULOS et al., "Anti-MUC1 Antibodies React Directly with MUC1 Peptides Presented by Class I H2 and HLA Molecules", The Journal of Immunology, Vol. 161, 1998, pp. 767-775, The American Association of Immunologists, Bethesda, MD
A-3	Nieves DOMENECH et al., "Identification of an HLA-A11-Restricted Epitope from the Tandem Repeat Domain of the Epithelial Tumor Antigen Mucin," The Journal of Immunology, Vol. 155, 1995, pp. 4766-4774, The American Association of Immunologists, Bethesda, MD
A-4	Vasso APOSTOLOPOULOS et al., "MUC1 Peptide Epitopes Associated with Five Different H-2 Class I Molecules", European Journal Of Immunology, Vol. 27, October 1997, pp. 2579-2587, Weinheim, Verlag Chemie GmbH, Germany
A-5	Isao NISHIMORI et al., "N-Acetylgalactosamine Glycosylation of MUC1 Tandem Repeat Peptides by Pancreatic Tumor Cell Extracts", Cancer Research, Vol. 54, 15 July 1994, pp. 3738-3744, The American Association of Immunologists, Bethesda, MD
A-6	Lior CARMON et al., "Novel Breast-Tumor-Associated MUC1-Derived Peptides: Characterization in D ^b -XB2 Microglobulin (B2m) Null Mice Transgenic For A Chimeric HLA-A2.1/D ^b B2 Microglobulin Single Chain", International Journal of Cancer, Vol. 85, No. 3, 1 February 2000, Wiley-Liss, New York, NY
A-7	Peter BROSSART et al., "Identification of HLA-A2-Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies", Blood, Vol. 93, No. 12, 15 June 1999, Grune & Stratton, New York
A-8	Babita AGRAWAL et al., "The Anti-MUC1 Monoclonal Antibody VCP8 Can Be Used to Isolate and Identify Putative Major Histocompatibility Complex Class I Associated Amine Acid", Cancer Research, Vol. 58, November 1998, pp. 5151-5156, The American Association of Immunologists, Bethesda, MD
A-9	Janice L. KAM et al., "MUC1 Synthetic Peptide Inhibition of Intercellular Adhesion Molecule-1 and MUC1 Binding Requires Six Tandem Repeats", Cancer Research, Vol. 58, December 1998, pp. 5577-5581, The American Association of Immunologists, Bethesda, MD
A-10	Geoffrey A. PIETERSZ et al., "Definition of MHC-Restricted CTL Epitopes from Non-Variable Number of Tandem Repeat Sequence of MUC1", Vaccine, Vol. 18, No. 19, April 2000, pp. 2059-2071, Butterworths, Guildford, Surrey, UK
A-11	Babita AGRAWAL et al., "In Vitro Induction of MUC-1 Peptide-Specific Type 1 T Lymphocyte and Cytotoxic T Lymphocyte Responses from Healthy Multiparous Donors", Cancer Research, Vol. 58, 15 November 1998, pp. 5151-5156, The American Association of Immunologists, Bethesda, MD
A-12	Vasso APOSTOLOPOULOS et al., "Induction of HLA-A2-Restricted CTLs to the Mucin 1 Human Breast Cancer Antigen", The Journal of Immunology, Vol. 159, 1997, pp. 5211-5218, The American Association of Immunologists, Bethesda, MD

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.